Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Biomarkers of aging serve as important outcome measures in longevity-promoting interventions. However, there is limited consensus on which specific biomarkers are most appropriate for human intervention studies. This work aimed to address this need by establishing an expert consensus on biomarkers of aging for use in intervention studies via the Delphi method. A 3-round Delphi study was conducted using an online platform. In Round 1, expert panel members provided suggestions for candidate biomarkers of aging. In Rounds 2 and 3, they voted on 500 initial statements (yes/no) relating to 20 biomarkers of aging. Panel members could abstain from voting on biomarkers outside their expertise. Consensus was reached when there was ≥70% agreement on a statement/biomarker. Of the 460 international panel members invited to participate, 116 completed Round 1, 87 completed Round 2, and 60 completed Round 3. Across the 3 rounds, 14 biomarkers met consensus that spanned physiological (eg, insulin-like growth factor 1, growth-differentiating factor-15), inflammatory (eg, high sensitivity C-reactive protein, interleukin-6), functional (eg, muscle mass, muscle strength, hand grip strength, Timed-Up-and-Go, gait speed, standing balance test, frailty index, cognitive health, blood pressure), and epigenetic (eg, DNA methylation/epigenetic clocks) domains. Expert consensus identified 14 potential biomarkers of aging which may be used as outcome measures in intervention studies. Future aging research should identify which combination of these biomarkers has the greatest utility.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11979094 | PMC |
| http://dx.doi.org/10.1093/gerona/glae297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.
J Prev Alzheimers Dis
September 2025
Stanford Neuroscience Health Center, Stanford University, Palo Alto CA USA.
Background: AR1001 is a phosphodiesterase-5 inhibitor that produces improved cognitive performance and reduces amyloid-β and phosphorylated tau burdens in preclinical models of Alzheimer's disease (AD).
Objectives: To evaluate the safety and efficacy of AR1001 in participants with mild-to-moderate Alzheimer's disease (AD).
Design: Randomized, double-blind, placebo-controlled phase 2 trial conducted at 21 sites in the United States.
Biliverdin reductase-A is a key modulator in insulin signaling and metabolism.
Trends Endocrinol Metab
September 2025
Department of Biochemical Sciences 'A. Rossi-Fanelli, ' Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy. Electronic address:
Biliverdin reductase-A (BVRA) is a pleiotropic enzyme traditionally known for its antioxidant role in the heme degradation pathway. Recent findings have redefined BVRA as a master regulator of insulin signaling, acting as a kinase, scaffold, and redox-sensitive integrator of metabolic cues. BVRA modulates key nodes of the insulin cascade and sustains mitochondrial and synaptic function.
View Article and Find Full Text PDFThe Glymphatic System and Sleep Dysfunction in Parkinson's Disease.
Sleep Med Clin
September 2025
Department of Clinical Research in Neurology, Center for Neurodegenerative Diseases and the Aging Brain, University of Bari 'Aldo Moro', "Pia Fondazione Cardinale G. Panico", Via San Pio X, 4, Tricase, Lecce 73039, Italy.
Parkinson's disease (PD) is characterized by both motor and nonmotor symptoms, including significant sleep disturbances. The glymphatic system, a brain-wide clearance mechanism active during sleep, may play a key role in PD pathology by impairing the removal of toxic proteins like α-synuclein. Dysfunctional glymphatic clearance and disrupted sleep may create a cycle that accelerates neurodegeneration.
View Article and Find Full Text PDFNuclear mitochondrial DNA transfer revisited: From genomic noise to hallmark of aging.
Ageing Res Rev
September 2025
Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy; Department of Medicine and Surgery, LUM University, Casamassima, Italy. Electronic address:
Nuclear insertions of mitochondrial DNA (mtDNA) segments (NUMTs) represent an evolutionarily conserved phenomenon originating from the ancient endosymbiotic relationship between mitochondria and host cells. These insertions predominantly localize near intergenic or regulatory regions and are often enriched in tissues with high metabolic activity. Once regarded as inert pseudogenes or genomic artifacts, NUMTs are now recognized as dynamic elements capable of modulating nuclear architecture and cellular function.
View Article and Find Full Text PDFEffect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study.
Cell Rep Med
August 2025
Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China; Jiangxi Clinical Research Center for Endocrine and Metabolic Disease, Nanchang, Jiangxi 330006, People's Republic of China; Jiangxi Branch of National C
Sodium-glucose cotransporter-2 inhibitors have been proposed as caloric restriction mimetics with potential anti-aging effects. However, clinical data on their influence on aging biomarkers are limited. In this multicenter, randomized, double-blind, placebo-controlled trial, 150 participants with type 2 diabetes are randomized (1:1) to receive oral henagliflozin (10 mg/day) or placebo for 26 weeks.
View Article and Find Full Text PDF